Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

gan Hing, Zachary A., Mantel, Rose, Beckwith, Kyle A., Guinn, Daphne, Williams, Erich, Smith, Lisa L., Williams, Katie, Johnson, Amy J., Lehman, Amy M., Byrd, John C., Woyach, Jennifer A., Lapalombella, Rosa
Cyhoeddwyd yn Blood (2015)

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients

gan Agrawal, Anant A., Seiler, Michael, Brinton, Lindsey T., Mantel, Rose, Lapalombella, Rosa, Woyach, Jennifer A., Johnson, Amy J., Zhu, Ping, Warmuth, Markus, Yu, Lihua, Byrd, John C., Smith, Peter G., Blachly, James S., Buonamici, Silvia
Cyhoeddwyd yn Blood Adv (2017)

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

gan Reiff, Sean D., Muhowski, Elizabeth M., Guinn, Daphne, Lehman, Amy, Fabian, Catherine A., Cheney, Carolyn, Mantel, Rose, Smith, Lisa, Johnson, Amy J., Young, Wendy B., Johnson, Adam R., Liu, Lichuan, Byrd, John C., Woyach, Jennifer A.
Cyhoeddwyd yn Blood (2018)

Targeting BTK through microRNA in chronic lymphocytic leukemia

gan Bottoni, Arianna, Rizzotto, Lara, Lai, Tzung-Huei, Liu, Chaomei, Smith, Lisa L., Mantel, Rose, Reiff, Sean, El-Gamal, Dalia, Larkin, Karilyn, Johnson, Amy J., Lapalombella, Rosa, Lehman, Amy, Plunkett, William, Byrd, John C., Blachly, James S., Woyach, Jennifer A., Sampath, Deepa
Cyhoeddwyd yn Blood (2016)

Eμ-TCL1xMyc: a novel mouse model for concurrent CLL and B-cell lymphoma

gan Lucas, Fabienne, Rogers, Kerry A., Harrington, Bonnie K., Pan, Alexander, Yu, Lianbo, Breitbach, Justin, Bundschuh, Ralf, Goettl, Virginia M., Hing, Zachary A., Kanga, Parviz, Mantel, Rose, Sampath, Deepa, Smith, Lisa L., Wasmuth, Ronni, White, Danielle K., Yan, Pearlly, Byrd, John C., Lapalombella, Rosa, Woyach, Jennifer A.
Cyhoeddwyd yn Clin Cancer Res (2019)

The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia

gan Herman, Sarah E. M., Montraveta, Arnau, Niemann, Carsten U., Mora-Jensen, Helena, Gulrajani, Michael, Krantz, Fanny, Mantel, Rose, Smith, Lisa L., McClanahan, Fabienne, Harrington, Bonnie K., Colomer, Dolors, Covey, Todd, Byrd, John C., Izumi, Raquel, Kaptein, Allard, Ulrich, Roger, Johnson, Amy J., Lannutti, Brian J., Wiestner, Adrian, Woyach, Jennifer A.
Cyhoeddwyd yn Clin Cancer Res (2016)

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

gan Woyach, Jennifer A., Smucker, Kelly, Smith, Lisa L., Lozanski, Arletta, Zhong, Yiming, Ruppert, Amy S., Lucas, David, Williams, Katie, Zhao, Weiqiang, Rassenti, Laura, Ghia, Emanuela, Kipps, Thomas J., Mantel, Rose, Jones, Jeffrey, Flynn, Joseph, Maddocks, Kami, O’Brien, Susan, Furman, Richard R., James, Danelle F., Clow, Fong, Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
Cyhoeddwyd 2014

Etiology of Ibrutinib Discontinuation and Outcomes in Chronic Lymphocytic Leukemia Patients

gan Maddocks, Kami J., Ruppert, Amy S., Lozanski, Gerard, Heerema, Nyla A., Zhao, Weiqiang, Abruzzo, Lynne, Lozanski, Arletta, Davis, Melanie, Gordon, Amber, Smith, Lisa L., Mantel, Rose, Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Andritsos, Leslie A., Awan, Farrukh, Blum, Kristie A., Grever, Michael R., Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Cyhoeddwyd yn JAMA Oncol (2015)

The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation

gan Reiff, Sean D., Mantel, Rose, Smith, Lisa L., Greene, JT, Muhowski, Elizabeth M., Fabian, Catherine A., Goettl, Virginia M., Tran, Minh, Harrington, Bonnie K., Rogers, Kerry A., Awan, Farrukh T., Maddocks, Kami, Andritsos, Leslie, Lehman, Amy M., Sampath, Deepa, Lapalombella, Rosa, Eathiraj, Sudharshan, Abbadessa, Giovanni, Schwartz, Brian, Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Cyhoeddwyd yn Cancer Discov (2018)

BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

gan Woyach, Jennifer A., Ruppert, Amy S., Guinn, Daphne, Lehman, Amy, Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
Cyhoeddwyd yn J Clin Oncol (2017)